We enter the third month of 2017 with biotechnology (IBB) stocks underperforming the markets. Nano-cap and companies with drugs only in the research pipeline are faring very poorly. As at last week (February 24), these biotech stocks could offer a 30 - 50% "bounce" on speculation alone. Fundamentals will not drive the share price.IntelliPharmaCeutics International Inc. (IPCI) soared on Feb 24. The FDA approved its generic version of Bristol-Myers Squibb's(BMY type 2 diabetes med Glucophage XR. $IPCIF, INTELLIPHARMACEUTICS INTL / D Kitov Pharmaceuticals Holdings LTD (KTOV )was granted a notice of allowance for KIT-302. Per the press release: "(KTOV is) an innovative biopharmaceutical company, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance to the Company related to claims expanding the patent coverage for its lead drug candidate, KIT-302, to include oral dosage compositions containing both amlodipine and celecoxib." $KTOV, Kitov Pharma Ltd. / D Ekso Bionics Holdings, Inc. (EKSO) is playing out as the pump and dump. The company reports results on March 7. In the last quarter, the robotic exoskeleton company reported preliminary revenue of $2.5 million. Full-year revenue of $14M includes a $6.5 million one-time deferred revenue item. $EKSO, Ekso Bionics Holdings, Inc. / D